



(12) Translation of
European patent specification

(11) NO/EP 3572405 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 235/22 (2006.01)

Norwegian Industrial Property Office


(45)	Translation Published	2023.11.13
(80)	Date of The European Patent Office Publication of the Granted Patent	2023.07.26
(86)	European Application Nr.	19185319.1
(86)	European Filing Date	2015.09.14
(87)	The European Application's Publication Date	2019.11.27
(30)	Priority	2014.09.12, US, 201462050023 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(62)	Divided application	EP3191457, 2015.09.14
(73)	Proprietor	Biohaven Therapeutics Ltd., 215 Church Street, New Haven, CT 06510, USA
(72)	Inventor	RESNICK, Lynn, 228 Cornwall Drive, Pittsburgh, Pennsylvania 15241, USA TOPALOV, George T, 3428 Brookdale Drive, Pittsburgh, Pennsylvania 15241, USA BOYD, Steven A., 345 Myoma Road, Mars, Pennsylvania 16046, USA BELARDI, Justin K., 1176 Windmill Lane, Pittsburgh, Pennsylvania 15237, USA FLENTGE, Charles A., 238 Adams Pointe Boulevard 5, Mars, Pennsylvania 16046, USA HALE, James S., 214 Amity Road, Glenshaw, Pennsylvania 15116, USA HARRIED, Scott S., 3061 W. Main Street, Sun Prairie, Wisconsin 53590, USA MARESKA, David A., 145 Hemlock Drive, McMurray, Pennsylvania 15317, USA ZHANG, Kai, 7102 Cresswyck Court, Wexford, Pennsylvania 15090, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54)	Title	BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS
(56)	References Cited:	US-A1- 2003 109 549

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. En forbindelse representert ved formelen:



5 hvor:

D er t-butyl;

A er C₁₋₈ alkyl;

X er H;

Y er H;

10 R¹ er Cl, Br, CN, OCH₃, eller CF₃;

R² er H, F, eller -CH₂OH;

R³ er H, F, Cl, Br eller I; og

R⁴ er H, -CH₃ eller -CF₃.

15 **2.** En forbindelse ifølge krav 1 for anvendelse ved behandling av epilepsi, smerte, migræne eller tinnitus.

3. En forbindelse for anvendelse i henhold til krav 2, hvor smerten er nevropatisk smerte, inflammatorisk smerte, vedvarende smerte, kreft smerte eller
20 postoperative smerte.

4. Forbindelsen ifølge krav 1 representert ved formelen:

